What Does Wall Street Think About Neurocrine Biosciences (NBIX)?

Group 1 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is currently viewed as one of the best drug stocks to buy, with RBC Capital raising its price target to $149 from $144 while maintaining an Outperform rating [1] - The company's drug Crenessity is expected to continue its strong launch, exceeding Q3 consensus estimates, indicating positive prescription trends [2] - Analyst consensus for Neurocrine Biosciences is Strong Buy, with a median price target of $141.87, suggesting a potential upside of 19.83% from current levels [3] Group 2 - Neurocrine Biosciences focuses on neuroscience and is involved in the research, development, sale, and commercialization of pharmaceuticals for neuroendocrine, neurological, and neuropsychiatric disorders [4] - The company's product portfolio includes treatments for conditions such as chorea associated with Huntington's disease, tardive dyskinesia, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids [4]